Coherus Oncology (CHRS) EPS (Weighted Average and Diluted) (2016 - 2025)
Coherus Oncology (CHRS) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.34 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 22.73% to -$0.34 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.6 through Dec 2025, down 280.95% year-over-year, with the annual reading at $1.43 for FY2025, 472.0% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.34 in Q4 2025 for Coherus Oncology, up from -$0.38 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.91 in Q1 2024 to a low of -$2.37 in Q1 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.61 across 5 years, with a median of -$0.49 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 690.0% in 2021 and later soared 194.79% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.59 in 2021, then decreased by 28.81% to -$0.76 in 2022, then increased by 2.63% to -$0.74 in 2023, then surged by 40.54% to -$0.44 in 2024, then increased by 22.73% to -$0.34 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for CHRS at -$0.34 in Q4 2025, -$0.38 in Q3 2025, and -$0.39 in Q2 2025.